Pradofloxacin: A novel veterinary fluoroquinolone for treatment of bacterial infections in cats

被引：21
|
作者：
Sykes, Jane E. [1 ,3 ,4 ]
Blondeau, Joseph M. [2 ,5 ]
机构：
[1] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA
[2] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Pathol & Lab Med, Saskatoon, SK S7N 0W8, Canada
[3] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Microbiol & Immunol, Saskatoon, SK S7N 0W8, Canada
[4] Saskatoon Hlth Reg, Royal Univ Hosp, Dept Ophthalmol, Saskatoon, SK S7N 0W8, Canada
[5] Univ Saskatchewan, Saskatoon, SK S7N 0W8, Canada
来源：
VETERINARY JOURNAL | 2014年 / 201卷 / 02期
关键词：
Antimicrobial; Minimum inhibitory concentration; Pharmacodynamics; Pharmacokinetics; Resistance; MUTANT PREVENTION CONCENTRATION; STREPTOCOCCUS-PNEUMONIAE; ESCHERICHIA-COLI; RETINAL DEGENERATION; SUSCEPTIBILITY; ENROFLOXACIN; RESISTANCE; SELECTION; AZITHROMYCIN; DOGS;
D O I：
10.1016/j.tvjl.2014.06.008
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
Pradofloxacin is a novel third-generation oral veterinary fluoroquinolone with activity against Gram-positive aerobic bacteria and anaerobes (lower minimum inhibitory concentrations in vitro). It also has activity against other bacterial species, including Bartonella henselae, Pasteurella multocida, Bordetella bronchiseptica, extra-intestinal Escherichia coli, and some mycobacterial species. This review focuses on the current knowledge of the mechanism of action, adverse effects, clinical applications, and pharmacokinetic/pharmacodynamic properties of pradofloxacin in cats. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：207 / 214
页数：8
相关论文
共 50 条
  • [31] Treatment and management of Chlamydophila felis infections in cats
    Hartmann, A.
    Hartmann, K.
    TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE, 2010, 38 (04): : 217 - +
  • [32] Ertapenem - A review of its use in the treatment of bacterial infections
    Keating, GM
    Perry, CM
    DRUGS, 2005, 65 (15) : 2151 - 2178
  • [33] Fighting bacterial infections-Future treatment options
    Fernebro, Jenny
    DRUG RESISTANCE UPDATES, 2011, 14 (02) : 125 - 139
  • [34] Daptotnycin in the treatment of invasive Gram-positive bacterial infections in children: personal experience
    Palma, D. M.
    Giordano, S.
    Cracchiolo, A. Neville
    Zangara, V.
    Coffaro, G.
    Tetamo, R.
    MINERVA PEDIATRICA, 2013, 65 (02) : 173 - 178
  • [35] Use of Essential Oils in Veterinary Medicine to Combat Bacterial and Fungal Infections
    Ebani, Valentina Virginia
    Mancianti, Francesca
    VETERINARY SCIENCES, 2020, 7 (04) : 1 - 35
  • [36] Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care β-Lactamase Characterization
    Palanisami, Akilan
    Khan, Shazia
    Erdem, Sultan Sibel
    Hasan, Tayyaba
    IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE, 2016, 4
  • [37] Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections
    Eljaaly, Khalid
    Alharbi, Aisha
    Alshehri, Samah
    Ortwine, Jessica K.
    Pogue, Jason M.
    DRUGS, 2019, 79 (03) : 243 - 269
  • [38] Genomic analysis of fluoroquinolone-susceptible phylogenetic group B2 extraintestinal pathogenic Escherichia coli causing infections in cats
    Kidsley, Amanda K.
    O'Dea, Mark
    Ebrahimie, Esmaeil
    Mohammadi-Dehcheshmeh, Manijeh
    Saputra, Sugiyono
    Jordan, David
    Johnson, James R.
    Gordon, David
    Turni, Conny
    Djordjevic, Steven P.
    Abraham, Sam
    Trott, Darren J.
    VETERINARY MICROBIOLOGY, 2020, 245 (00)
  • [39] Visualizing Bacterial Infections With Novel Targeted Molecular Imaging Approaches
    Chen, Xueyi
    Gallagher, Ferdia
    Sellmyer, Mark A.
    Ordonez, Alvaro A.
    Kjaer, Andreas
    Ohliger, Michael
    Wilson, David M.
    Jain, Sanjay K.
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S249 - S258
  • [40] Besifloxacin Ophthalmic Suspension, 0.6%: a Novel Topical Fluoroquinolone for Bacterial Conjunctivitis
    O'Brien, Terrence P.
    ADVANCES IN THERAPY, 2012, 29 (06) : 473 - 490
12345